Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Movember ? the world's leading men's health charity ? has released the Real Face of Men's Health Report (the report) detailing new findings on the state of men's health in Canada. The report reveals ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

P-Cure, a global innovator in compact proton therapy solutions, has announced the inauguration of its?second production facility?in Israel. This new building, adjacent to the existing P-Cure facility, ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...